Skip to content

CagriSema vs Retatrutide

Updated 9 sources

Key differences

  1. 1No head-to-head trial. Retatrutide 12 mg reached 24.2% weight loss at 48 weeks in its phase 2 trial; CagriSema reached 20.4% at 68 weeks in REDEFINE 1 (treatment policy). Different trials and populations.
  2. 2Retatrutide is one molecule hitting GLP-1, GIP and glucagon receptors; CagriSema is two molecules hitting amylin and GLP-1 receptors.

Side by side

Facts from each record, in the same words as their own pages.
CagriSema and Retatrutide side by side
CagriSemaRetatrutide
Category
  • Weight loss, GLP-1
  • GLP-1, Weight loss
Evidence
  • Strong human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • In clinical trialsRegulatory
WADA
  • Not confirmed
  • Not confirmed
Half-life
  • Cagrilintide component: 159 to 195 hours, peaking 24 to 72 hours after a dose (phase 1b, given with semaglutide).Clinical study
  • Semaglutide component: 145 to 165 hours, peaking 12 to 24 hours after a dose (same trial).Clinical study
  • About 6 days in the phase 1b trial, with exposure rising in proportion to dose. Built for once-weekly shots.Clinical study
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Vial (powder)
Not reported
Reported doses
  • 0.16 to 4.5 mg (subcutaneous injection)
  • 0.25 to 12 mg (subcutaneous injection)
Most cited frequency
  • Once weekly, cagrilintide and semaglutide at the same mg (2.4 mg + 2.4 mg at maintenance)
  • Once weekly. Start at 2 mg, step up every 4 weeks to a target of 4, 9 or 12 mg, then hold.
Vial sizes
  • 5 mg, 10 mg, 20 mgVendor guide
  • 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps
  • Fridge at 2 to 8 °C, use within 30 days.Vendor guide
  • Keep the mixed vial in the fridge and use it within about 28 days.Community-reported
Protocols on file
  • 6
  • 18

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory2

  1. openFDA Drugs@FDA query for cagrilintideFDA (openFDA) · checked Oct 24, 2026
  2. NCT05567796 (REDEFINE 1), phase 3, active not recruitingClinicalTrials.gov · checked Oct 24, 2026